1. Phylogeny  
   Cyclin-dependent kinase 5 (CDK5), also known as PSSALRE, is classified within the cyclin-dependent kinase family but diverges markedly from classical cell cycle Cdks due to its unique regulatory activators and neuronal functions. CDK5 is highly conserved across mammalian species, with over 99% amino acid identity reported between human and bovine homologs, and its orthologs in higher eukaryotes share significant sequence similarity, whereas homologs identified in Drosophila melanogaster and Caenorhabditis elegans show lower identity percentages, indicating divergence in lower organisms (tang1996cyclindependentkinase5 pages 1-2). Phylogenetically, CDK5 groups with other Cdks that have evolved to execute specialized roles outside of cell cycle regulation; it has been traced back to an ancient eukaryotic kinase lineage that also gave rise to yeast Pho85, although CDK5 activation no longer depends on classical cyclins, reflecting its adaptation to neuronal contexts (malumbres2014cyclindependentkinases pages 6-7, tang1996cyclindependentkinase5 pages 1-2). Its evolution into a kinase that is activated by neuron-specific proteins such as p35 and p39 distinguishes it from other members of the family, which maintain cyclin-dependent activation mechanisms (łukasik2021cyclindependentkinases(cdk) pages 2-4, su2011cyclindependentkinasesin pages 1-3).
2. Reaction Catalyzed  
   CDK5 catalyzes the transfer of a phosphate group from adenosine triphosphate (ATP) to the hydroxyl group on the serine or threonine residues of substrate proteins. The chemical reaction can be summarized as follows: ATP + [protein]-(L-serine/L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺, which is the canonical phosphoryl transfer reaction found in serine/threonine kinases (bhounsule2017cyclindependentkinase pages 6-10).
3. Cofactor Requirements  
   The catalytic activity of CDK5 relies on divalent cations, with Mg²⁺ serving as an essential cofactor that facilitates ATP binding and the proper orientation of the nucleotide for phosphoryl transfer. This requirement for Mg²⁺ is consistent with the cofactor dependency observed in other members of the CDK family (malumbres2014cyclindependentkinases pages 2-3).
4. Substrate Specificity  
   CDK5 functions as a proline-directed serine/threonine kinase and exhibits a substrate specificity that centers on phosphorylating serine or threonine residues that are immediately followed by a proline. This substrate specificity is reflected in its ability to phosphorylate a variety of proteins containing such a consensus motif, which often is represented as S/T-P, and may include additional determinants dictated by the substrate’s surrounding amino acid context. For example, CDK5 preferentially phosphorylates proteins such as tau, MAP2, and various cytoskeletal proteins that bear these proline-directed motifs (su2011cyclindependentkinasesin pages 7-9, bhounsule2017cyclindependentkinase pages 43-52, kesavapany2004neuronalcyclindependentkinase pages 1-2). Subsequent substrate recognition studies indicate that additional residues flanking the core S/T-P motif may influence binding affinity and phosphorylation efficiency, thereby fine-tuning its activity on complex substrates involved in neuronal morphology and synaptic regulation (chou1999amodelof pages 1-3, malumbres2014cyclindependentkinases pages 3-5).
5. Structure  
   CDK5 is composed of a conserved protein kinase domain that is common to all cyclin-dependent kinases, which includes a small N-terminal lobe composed predominantly of β-sheets and a larger C-terminal lobe largely consisting of α-helices. The active site, situated at the interface of these lobes, harbors an ATP-binding pocket and accommodates catalytic metals such as Mg²⁺. Unique regulatory features of CDK5 include an activation or T-loop region that contains key residues like Ser159; phosphorylation of this residue, as observed in studies, modulates kinase activity (sharma1999regulationofcyclindependent pages 1-2). Structural evidence further indicates that despite the high degree of conservation in the kinase fold, CDK5 lacks certain cyclin-binding elements present in classic cell cycle CDKs and instead interacts with non-cyclin activators such as p35 and p39, which induce the necessary conformational changes for catalytic activation (tang1996cyclindependentkinase5 pages 1-2, bhounsule2017cyclindependentkinase pages 1-6). The three-dimensional organization of CDK5 shows conservation of key catalytic motifs such as the glycine-rich loop (G-loop) and a C-helix that is repositioned upon activator binding. In addition, the hydrophobic spine, which is essential for aligning catalytic residues, is present in CDK5 and contributes to its unique substrate specificity and regulation (sharma1999regulationofcyclindependent pages 3-4, malumbres2014cyclindependentkinases pages 5-6).
6. Regulation  
   The regulation of CDK5 occurs primarily through its association with neuron-specific activators, such as p35 and p39, which are necessary to induce a catalytically active conformation. Unlike classical Cdks that depend on multiple cyclins and phosphorylation by CDK-activating kinases, CDK5 is activated by binding to these specific activators, which also determine its subcellular localization and substrate specificity (kesavapany2004neuronalcyclindependentkinase pages 2-4, tang1996cyclindependentkinase5 pages 1-2). Post-translational modifications also play a critical role; phosphorylation of CDK5 at Ser159 is essential for its full catalytic activity, with casein kinase I (CKI) identified as a kinase capable of phosphorylating this residue in vitro, thereby enhancing its activity in complex with p25, a proteolytic product of p35 that is implicated in neurodegenerative processes (sharma1999regulationofcyclindependent pages 1-2, sharma1999regulationofcyclindependent pages 4-5). Furthermore, the cleavage of p35 to p25 by calpain not only increases the stability of the CDK5 complex but also redistributes its activity within neuronal cells, a process that has been closely associated with pathological hyperphosphorylation of substrates such as tau in Alzheimer’s disease (bhounsule2017cyclindependentkinase pages 19-23, su2011cyclindependentkinasesin pages 21-23). In addition to phosphorylation, other regulatory mechanisms include protein–protein interactions with substrates and anchoring proteins that facilitate spatially restricted kinase activity, thereby ensuring that CDK5 functions precisely within neuronal processes such as axonal guidance and synaptic vesicle cycling (kesavapany2004neuronalcyclindependentkinase pages 8-9, su2011cyclindependentkinasesin pages 23-24).
7. Function  
   CDK5 plays a multifaceted role in the regulation of neuronal development, maintenance, and survival. It is predominantly expressed in post-mitotic neurons and is integral to processes such as neuronal migration, axonal and dendritic outgrowth, and synaptogenesis. CDK5 phosphorylates a wide array of substrates that mediate diverse neuronal functions, including the regulation of cytoskeletal dynamics through modification of tau, MAP2, and MAP1B, which in turn influences microtubule stability and neurite growth (bhounsule2017cyclindependentkinase pages 6-10, su2011cyclindependentkinasesin pages 7-9). It also phosphorylates proteins involved in the synaptic vesicle cycle such as synapsin I, dynamin1, and amphiphysin, thereby modulating neurotransmitter release and synaptic plasticity (kesavapany2004neuronalcyclindependentkinase pages 5-6, rosales2006extraneuronalrolesof pages 5-7). Beyond these roles, CDK5 functions to promote neuronal survival by activating anti-apoptotic pathways that involve BCL2 and STAT3, while concurrently inhibiting pro-apoptotic signals such as JNK3/MAPK10 activity (bhounsule2017cyclindependentkinase pages 43-52, su2011cyclindependentkinasesin pages 20-21). In addition, CDK5 is implicated in the regulation of the circadian clock via phosphorylation of CLOCK protein, modulation of N-cadherin-mediated adhesion at synapses, and negative regulation of pathways such as Wnt/β-catenin signaling, thereby influencing both neuronal physiology and pathological states (bhounsule2017cyclindependentkinase pages 19-23, su2011cyclindependentkinasesin pages 23-24). CDK5 also plays roles outside the central nervous system, including modulation of endothelial cell migration and angiogenesis, as well as contributing to the regulation of proinflammatory pathways via the GAIT complex in myeloid cells (rosales2006extraneuronalrolesof pages 9-10, łukasik2021cyclindependentkinases(cdk) pages 30-31).
8. Other Comments  
   Experimental inhibitors, such as roscovitine and related small molecules, have been used to target CDK5 activity in preclinical studies, with the aim of mitigating its aberrant activity observed in neurodegenerative diseases like Alzheimer’s and amyotrophic lateral sclerosis (knockaert2002pharmacologicalinhibitorsof pages 5-6, su2011cyclindependentkinasesin pages 17-18). Disease associations are well documented, with hyperactivation of CDK5—particularly in the context of p25 accumulation—being linked to pathological tau hyperphosphorylation, double-strand DNA damage, deregulation of HDAC1, and subsequent neuronal cell death (bhounsule2017cyclindependentkinase pages 19-23, depinho2003decreasedcyclindependentkinase pages 9-10). Furthermore, mutations or dysregulation in CDK5 signaling components have been implicated in disrupted synaptic plasticity, cognitive dysfunction, and eventual neurodegeneration (su2011cyclindependentkinasesin pages 24-26, tang1996cyclindependentkinase5 pages 7-8). No specific disease-causing mutations in the CDK5 coding region are reported in the current context; however, modulation of its activity via altered expression or aberrant cleavage of its activator p35 to p25 constitutes one of the primary pathogenic mechanisms, making its regulatory network a focus for therapeutic intervention (bhounsule2017cyclindependentkinase pages 1-6, kesavapany2004neuronalcyclindependentkinase pages 1-2).
9. References
10. bhounsule2017cyclindependentkinase pages 1-6
11. bhounsule2017cyclindependentkinase pages 6-10
12. bhounsule2017cyclindependentkinase pages 19-23
13. bhounsule2017cyclindependentkinase pages 43-52
14. chou1999amodelof pages 1-3
15. kesavapany2004neuronalcyclindependentkinase pages 1-2
16. kesavapany2004neuronalcyclindependentkinase pages 2-4
17. kesavapany2004neuronalcyclindependentkinase pages 4-5
18. kesavapany2004neuronalcyclindependentkinase pages 5-6
19. kesavapany2004neuronalcyclindependentkinase pages 8-9
20. malumbres2014cyclindependentkinases pages 1-2
21. malumbres2014cyclindependentkinases pages 2-3
22. malumbres2014cyclindependentkinases pages 3-5
23. malumbres2014cyclindependentkinases pages 5-6
24. malumbres2014cyclindependentkinases pages 6-7
25. malumbres2014cyclindependentkinases pages 8-9
26. malumbres2009cyclindependentkinasesa pages 2-4
27. pareek2006cyclindependentkinase5 pages 1-1
28. rosales2006extraneuronalrolesof pages 2-3
29. rosales2006extraneuronalrolesof pages 3-5
30. rosales2006extraneuronalrolesof pages 5-7
31. rosales2006extraneuronalrolesof pages 9-10
32. sharma1999regulationofcyclindependent pages 1-2
33. sharma1999regulationofcyclindependent pages 3-4
34. sharma1999regulationofcyclindependent pages 4-5
35. su2011cyclindependentkinasesin pages 1-3
36. su2011cyclindependentkinasesin pages 6-7
37. su2011cyclindependentkinasesin pages 7-9
38. su2011cyclindependentkinasesin pages 17-18
39. su2011cyclindependentkinasesin pages 18-20
40. su2011cyclindependentkinasesin pages 20-21
41. su2011cyclindependentkinasesin pages 21-23
42. su2011cyclindependentkinasesin pages 23-24
43. su2011cyclindependentkinasesin pages 24-26
44. tang1996cyclindependentkinase5 pages 1-2
45. tang1996cyclindependentkinase5 pages 2-4
46. tang1996cyclindependentkinase5 pages 6-7
47. tang1996cyclindependentkinase5 pages 7-8
48. łukasik2021cyclindependentkinases(cdk) pages 2-4
49. łukasik2021cyclindependentkinases(cdk) pages 23-25
50. łukasik2021cyclindependentkinases(cdk) pages 29-30
51. łukasik2021cyclindependentkinases(cdk) pages 30-31
52. knockaert2002pharmacologicalinhibitorsof pages 1-2
53. knockaert2002pharmacologicalinhibitorsof pages 2-3
54. knockaert2002pharmacologicalinhibitorsof pages 3-4
55. knockaert2002pharmacologicalinhibitorsof pages 5-6
56. knockaert2002pharmacologicalinhibitorsof pages 8-9
57. depinho2003decreasedcyclindependentkinase pages 9-10

References

1. (bhounsule2017cyclindependentkinase pages 19-23): Anisha S. Bhounsule, Lokesh Kumar Bhatt, Kedar S. Prabhavalkar, and Manisha Oza. Cyclin dependent kinase 5: a novel avenue for alzheimer’s disease. Brain Research Bulletin, 132:28-38, Jun 2017. URL: https://doi.org/10.1016/j.brainresbull.2017.05.006, doi:10.1016/j.brainresbull.2017.05.006. This article has 47 citations and is from a peer-reviewed journal.
2. (bhounsule2017cyclindependentkinase pages 43-52): Anisha S. Bhounsule, Lokesh Kumar Bhatt, Kedar S. Prabhavalkar, and Manisha Oza. Cyclin dependent kinase 5: a novel avenue for alzheimer’s disease. Brain Research Bulletin, 132:28-38, Jun 2017. URL: https://doi.org/10.1016/j.brainresbull.2017.05.006, doi:10.1016/j.brainresbull.2017.05.006. This article has 47 citations and is from a peer-reviewed journal.
3. (bhounsule2017cyclindependentkinase pages 6-10): Anisha S. Bhounsule, Lokesh Kumar Bhatt, Kedar S. Prabhavalkar, and Manisha Oza. Cyclin dependent kinase 5: a novel avenue for alzheimer’s disease. Brain Research Bulletin, 132:28-38, Jun 2017. URL: https://doi.org/10.1016/j.brainresbull.2017.05.006, doi:10.1016/j.brainresbull.2017.05.006. This article has 47 citations and is from a peer-reviewed journal.
4. (chou1999amodelof pages 1-3): Kuo-Chen Chou, Keith D. Watenpaugh, and Robert L. Heinrikson. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal cdk5 activator. Biochemical and biophysical research communications, 259 2:420-8, Jun 1999. URL: https://doi.org/10.1006/bbrc.1999.0792, doi:10.1006/bbrc.1999.0792. This article has 210 citations and is from a peer-reviewed journal.
5. (kesavapany2004neuronalcyclindependentkinase pages 2-4): Sashi Kesavapany, Bing-Sheng Li, Niranjana Amin, Ya-Li Zheng, Philip Grant, and Harish C. Pant. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the cdk5 inhibitory peptide. Biochimica et biophysica acta, 1697 1-2:143-53, Mar 2004. URL: https://doi.org/10.1016/j.bbapap.2003.11.020, doi:10.1016/j.bbapap.2003.11.020. This article has 96 citations.
6. (malumbres2014cyclindependentkinases pages 6-7): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
7. (pareek2006cyclindependentkinase5 pages 1-1): Tej K. Pareek, Jason Keller, Sashi Kesavapany, Harish C. Pant, Michael J. Iadarola, Roscoe O. Brady, and Ashok B. Kulkarni. Cyclin-dependent kinase 5 activity regulates pain signaling. Proceedings of the National Academy of Sciences of the United States of America, 103 3:791-6, Jan 2006. URL: https://doi.org/10.1073/pnas.0510405103, doi:10.1073/pnas.0510405103. This article has 175 citations and is from a highest quality peer-reviewed journal.
8. (su2011cyclindependentkinasesin pages 1-3): Susan C. Su and Li-Huei Tsai. Cyclin-dependent kinases in brain development and disease. Annual Review of Cell and Developmental Biology, 27:465-491, Nov 2011. URL: https://doi.org/10.1146/annurev-cellbio-092910-154023, doi:10.1146/annurev-cellbio-092910-154023. This article has 356 citations and is from a domain leading peer-reviewed journal.
9. (su2011cyclindependentkinasesin pages 24-26): Susan C. Su and Li-Huei Tsai. Cyclin-dependent kinases in brain development and disease. Annual Review of Cell and Developmental Biology, 27:465-491, Nov 2011. URL: https://doi.org/10.1146/annurev-cellbio-092910-154023, doi:10.1146/annurev-cellbio-092910-154023. This article has 356 citations and is from a domain leading peer-reviewed journal.
10. (tang1996cyclindependentkinase5 pages 1-2): Damu Tang and Jerry H. Wang. Cyclin-dependent kinase 5 (cdk5) and neuron-specific cdk5 activators. Progress in Cell Cycle Research, 2:205-216, Jan 1996. URL: https://doi.org/10.1007/978-1-4615-5873-6\_20, doi:10.1007/978-1-4615-5873-6\_20. This article has 98 citations.
11. (łukasik2021cyclindependentkinases(cdk) pages 2-4): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 199 citations and is from a peer-reviewed journal.
12. (łukasik2021cyclindependentkinases(cdk) pages 23-25): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 199 citations and is from a peer-reviewed journal.
13. (łukasik2021cyclindependentkinases(cdk) pages 29-30): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 199 citations and is from a peer-reviewed journal.
14. (łukasik2021cyclindependentkinases(cdk) pages 30-31): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 199 citations and is from a peer-reviewed journal.
15. (bhounsule2017cyclindependentkinase pages 1-6): Anisha S. Bhounsule, Lokesh Kumar Bhatt, Kedar S. Prabhavalkar, and Manisha Oza. Cyclin dependent kinase 5: a novel avenue for alzheimer’s disease. Brain Research Bulletin, 132:28-38, Jun 2017. URL: https://doi.org/10.1016/j.brainresbull.2017.05.006, doi:10.1016/j.brainresbull.2017.05.006. This article has 47 citations and is from a peer-reviewed journal.
16. (depinho2003decreasedcyclindependentkinase pages 9-10): RA DePinho. Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein …. Unknown journal, 2003.
17. (kesavapany2004neuronalcyclindependentkinase pages 1-2): Sashi Kesavapany, Bing-Sheng Li, Niranjana Amin, Ya-Li Zheng, Philip Grant, and Harish C. Pant. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the cdk5 inhibitory peptide. Biochimica et biophysica acta, 1697 1-2:143-53, Mar 2004. URL: https://doi.org/10.1016/j.bbapap.2003.11.020, doi:10.1016/j.bbapap.2003.11.020. This article has 96 citations.
18. (kesavapany2004neuronalcyclindependentkinase pages 4-5): Sashi Kesavapany, Bing-Sheng Li, Niranjana Amin, Ya-Li Zheng, Philip Grant, and Harish C. Pant. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the cdk5 inhibitory peptide. Biochimica et biophysica acta, 1697 1-2:143-53, Mar 2004. URL: https://doi.org/10.1016/j.bbapap.2003.11.020, doi:10.1016/j.bbapap.2003.11.020. This article has 96 citations.
19. (kesavapany2004neuronalcyclindependentkinase pages 5-6): Sashi Kesavapany, Bing-Sheng Li, Niranjana Amin, Ya-Li Zheng, Philip Grant, and Harish C. Pant. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the cdk5 inhibitory peptide. Biochimica et biophysica acta, 1697 1-2:143-53, Mar 2004. URL: https://doi.org/10.1016/j.bbapap.2003.11.020, doi:10.1016/j.bbapap.2003.11.020. This article has 96 citations.
20. (kesavapany2004neuronalcyclindependentkinase pages 8-9): Sashi Kesavapany, Bing-Sheng Li, Niranjana Amin, Ya-Li Zheng, Philip Grant, and Harish C. Pant. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the cdk5 inhibitory peptide. Biochimica et biophysica acta, 1697 1-2:143-53, Mar 2004. URL: https://doi.org/10.1016/j.bbapap.2003.11.020, doi:10.1016/j.bbapap.2003.11.020. This article has 96 citations.
21. (knockaert2002pharmacologicalinhibitorsof pages 1-2): Marie Knockaert, Paul Greengard, and Laurent Meijer. Pharmacological inhibitors of cyclin-dependent kinases. Trends in Pharmacological Sciences, 23:417-425, Sep 2002. URL: https://doi.org/10.1016/s0165-6147(02)02071-0, doi:10.1016/s0165-6147(02)02071-0. This article has 741 citations and is from a highest quality peer-reviewed journal.
22. (knockaert2002pharmacologicalinhibitorsof pages 2-3): Marie Knockaert, Paul Greengard, and Laurent Meijer. Pharmacological inhibitors of cyclin-dependent kinases. Trends in Pharmacological Sciences, 23:417-425, Sep 2002. URL: https://doi.org/10.1016/s0165-6147(02)02071-0, doi:10.1016/s0165-6147(02)02071-0. This article has 741 citations and is from a highest quality peer-reviewed journal.
23. (knockaert2002pharmacologicalinhibitorsof pages 3-4): Marie Knockaert, Paul Greengard, and Laurent Meijer. Pharmacological inhibitors of cyclin-dependent kinases. Trends in Pharmacological Sciences, 23:417-425, Sep 2002. URL: https://doi.org/10.1016/s0165-6147(02)02071-0, doi:10.1016/s0165-6147(02)02071-0. This article has 741 citations and is from a highest quality peer-reviewed journal.
24. (knockaert2002pharmacologicalinhibitorsof pages 5-6): Marie Knockaert, Paul Greengard, and Laurent Meijer. Pharmacological inhibitors of cyclin-dependent kinases. Trends in Pharmacological Sciences, 23:417-425, Sep 2002. URL: https://doi.org/10.1016/s0165-6147(02)02071-0, doi:10.1016/s0165-6147(02)02071-0. This article has 741 citations and is from a highest quality peer-reviewed journal.
25. (knockaert2002pharmacologicalinhibitorsof pages 8-9): Marie Knockaert, Paul Greengard, and Laurent Meijer. Pharmacological inhibitors of cyclin-dependent kinases. Trends in Pharmacological Sciences, 23:417-425, Sep 2002. URL: https://doi.org/10.1016/s0165-6147(02)02071-0, doi:10.1016/s0165-6147(02)02071-0. This article has 741 citations and is from a highest quality peer-reviewed journal.
26. (malumbres2009cyclindependentkinasesa pages 2-4): Marcos Malumbres, Edward Harlow, Tim Hunt, Tony Hunter, Jill M. Lahti, Gerard Manning, David O. Morgan, Li-Huei Tsai, and Debra J. Wolgemuth. Cyclin-dependent kinases: a family portrait. Nature Cell Biology, 11:1275-1276, Nov 2009. URL: https://doi.org/10.1038/ncb1109-1275, doi:10.1038/ncb1109-1275. This article has 582 citations and is from a highest quality peer-reviewed journal.
27. (malumbres2014cyclindependentkinases pages 1-2): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
28. (malumbres2014cyclindependentkinases pages 2-3): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
29. (malumbres2014cyclindependentkinases pages 3-5): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
30. (malumbres2014cyclindependentkinases pages 5-6): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
31. (malumbres2014cyclindependentkinases pages 8-9): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
32. (rosales2006extraneuronalrolesof pages 2-3): Jesusa L. Rosales and Ki‐Young Lee. Extraneuronal roles of cyclin‐dependent kinase 5. BioEssays, Oct 2006. URL: https://doi.org/10.1002/bies.20473, doi:10.1002/bies.20473. This article has 155 citations and is from a peer-reviewed journal.
33. (rosales2006extraneuronalrolesof pages 3-5): Jesusa L. Rosales and Ki‐Young Lee. Extraneuronal roles of cyclin‐dependent kinase 5. BioEssays, Oct 2006. URL: https://doi.org/10.1002/bies.20473, doi:10.1002/bies.20473. This article has 155 citations and is from a peer-reviewed journal.
34. (rosales2006extraneuronalrolesof pages 5-7): Jesusa L. Rosales and Ki‐Young Lee. Extraneuronal roles of cyclin‐dependent kinase 5. BioEssays, Oct 2006. URL: https://doi.org/10.1002/bies.20473, doi:10.1002/bies.20473. This article has 155 citations and is from a peer-reviewed journal.
35. (rosales2006extraneuronalrolesof pages 9-10): Jesusa L. Rosales and Ki‐Young Lee. Extraneuronal roles of cyclin‐dependent kinase 5. BioEssays, Oct 2006. URL: https://doi.org/10.1002/bies.20473, doi:10.1002/bies.20473. This article has 155 citations and is from a peer-reviewed journal.
36. (sharma1999regulationofcyclindependent pages 1-2): Pushkar Sharma, Monica Sharma, Niranjana D. Amin, R. Wayne Albers, and Harish C. Pant. Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proceedings of the National Academy of Sciences, 96:11156-11160, Sep 1999. URL: https://doi.org/10.1073/pnas.96.20.11156, doi:10.1073/pnas.96.20.11156. This article has 143 citations.
37. (sharma1999regulationofcyclindependent pages 3-4): Pushkar Sharma, Monica Sharma, Niranjana D. Amin, R. Wayne Albers, and Harish C. Pant. Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proceedings of the National Academy of Sciences, 96:11156-11160, Sep 1999. URL: https://doi.org/10.1073/pnas.96.20.11156, doi:10.1073/pnas.96.20.11156. This article has 143 citations.
38. (sharma1999regulationofcyclindependent pages 4-5): Pushkar Sharma, Monica Sharma, Niranjana D. Amin, R. Wayne Albers, and Harish C. Pant. Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proceedings of the National Academy of Sciences, 96:11156-11160, Sep 1999. URL: https://doi.org/10.1073/pnas.96.20.11156, doi:10.1073/pnas.96.20.11156. This article has 143 citations.
39. (su2011cyclindependentkinasesin pages 17-18): Susan C. Su and Li-Huei Tsai. Cyclin-dependent kinases in brain development and disease. Annual Review of Cell and Developmental Biology, 27:465-491, Nov 2011. URL: https://doi.org/10.1146/annurev-cellbio-092910-154023, doi:10.1146/annurev-cellbio-092910-154023. This article has 356 citations and is from a domain leading peer-reviewed journal.
40. (su2011cyclindependentkinasesin pages 18-20): Susan C. Su and Li-Huei Tsai. Cyclin-dependent kinases in brain development and disease. Annual Review of Cell and Developmental Biology, 27:465-491, Nov 2011. URL: https://doi.org/10.1146/annurev-cellbio-092910-154023, doi:10.1146/annurev-cellbio-092910-154023. This article has 356 citations and is from a domain leading peer-reviewed journal.
41. (su2011cyclindependentkinasesin pages 20-21): Susan C. Su and Li-Huei Tsai. Cyclin-dependent kinases in brain development and disease. Annual Review of Cell and Developmental Biology, 27:465-491, Nov 2011. URL: https://doi.org/10.1146/annurev-cellbio-092910-154023, doi:10.1146/annurev-cellbio-092910-154023. This article has 356 citations and is from a domain leading peer-reviewed journal.
42. (su2011cyclindependentkinasesin pages 21-23): Susan C. Su and Li-Huei Tsai. Cyclin-dependent kinases in brain development and disease. Annual Review of Cell and Developmental Biology, 27:465-491, Nov 2011. URL: https://doi.org/10.1146/annurev-cellbio-092910-154023, doi:10.1146/annurev-cellbio-092910-154023. This article has 356 citations and is from a domain leading peer-reviewed journal.
43. (su2011cyclindependentkinasesin pages 23-24): Susan C. Su and Li-Huei Tsai. Cyclin-dependent kinases in brain development and disease. Annual Review of Cell and Developmental Biology, 27:465-491, Nov 2011. URL: https://doi.org/10.1146/annurev-cellbio-092910-154023, doi:10.1146/annurev-cellbio-092910-154023. This article has 356 citations and is from a domain leading peer-reviewed journal.
44. (su2011cyclindependentkinasesin pages 6-7): Susan C. Su and Li-Huei Tsai. Cyclin-dependent kinases in brain development and disease. Annual Review of Cell and Developmental Biology, 27:465-491, Nov 2011. URL: https://doi.org/10.1146/annurev-cellbio-092910-154023, doi:10.1146/annurev-cellbio-092910-154023. This article has 356 citations and is from a domain leading peer-reviewed journal.
45. (su2011cyclindependentkinasesin pages 7-9): Susan C. Su and Li-Huei Tsai. Cyclin-dependent kinases in brain development and disease. Annual Review of Cell and Developmental Biology, 27:465-491, Nov 2011. URL: https://doi.org/10.1146/annurev-cellbio-092910-154023, doi:10.1146/annurev-cellbio-092910-154023. This article has 356 citations and is from a domain leading peer-reviewed journal.
46. (tang1996cyclindependentkinase5 pages 2-4): Damu Tang and Jerry H. Wang. Cyclin-dependent kinase 5 (cdk5) and neuron-specific cdk5 activators. Progress in Cell Cycle Research, 2:205-216, Jan 1996. URL: https://doi.org/10.1007/978-1-4615-5873-6\_20, doi:10.1007/978-1-4615-5873-6\_20. This article has 98 citations.
47. (tang1996cyclindependentkinase5 pages 6-7): Damu Tang and Jerry H. Wang. Cyclin-dependent kinase 5 (cdk5) and neuron-specific cdk5 activators. Progress in Cell Cycle Research, 2:205-216, Jan 1996. URL: https://doi.org/10.1007/978-1-4615-5873-6\_20, doi:10.1007/978-1-4615-5873-6\_20. This article has 98 citations.
48. (tang1996cyclindependentkinase5 pages 7-8): Damu Tang and Jerry H. Wang. Cyclin-dependent kinase 5 (cdk5) and neuron-specific cdk5 activators. Progress in Cell Cycle Research, 2:205-216, Jan 1996. URL: https://doi.org/10.1007/978-1-4615-5873-6\_20, doi:10.1007/978-1-4615-5873-6\_20. This article has 98 citations.